Lumexa Imaging Holdings, Inc. (LMRI)
Nasdaq · Services-Medical Laboratories · Services · CIK 2071288 · fiscal year ends in Dec
Closing price $11.40 on 30 Oct 2026; 52-week range $6.77 to $18.53.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $1.1B
- Cash
- $69.7M
- Debt
- $835.4M
- Debt to equity
- 1.36
- Shares outstanding
- 96.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $264.2M | $2.7M | $0.03 |
| Q1 FY2026 | 31 Mar 2026 | $252.5M | $1.7M | $0.02 |
| Q2 FY2025 | 30 Jun 2025 | $251.4M | -$7.2M | -$0.10 |
| Q1 FY2025 | 31 Mar 2025 | $245.0M | -$7.7M | -$0.11 |
Company events
The newest 8-K filings of 10 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 12 Aug 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 30 Jun 2026 | 8-K | Material agreement, New debt | 1.01, 2.03, 9.01 |
| 12 Jun 2026 | 8-K | Shareholder vote | 5.07, 9.01 |
| 12 May 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 9 Apr 2026 | 8-K | Investor update | 7.01 |
| 26 Mar 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 2 Mar 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 15 Jan 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 18 Dec 2025 | 8-K | Material agreement, New debt | 1.01, 2.03, 9.01 |
| 12 Dec 2025 | 8-K | Leadership change, Material agreement, Bylaws or fiscal year change, Other events | 1.01, 5.02, 5.03, 8.01, 9.01 |
Every filing
The newest filings with the SEC of 37 held.
| Filed | Form | Period |
|---|---|---|
| 13 Aug 2026 | 10-Q | 30 Jun 2026 |
| 12 Aug 2026 | 8-K | 12 Aug 2026 |
| 30 Jun 2026 | 8-K | 30 Jun 2026 |
| 12 Jun 2026 | 8-K | 10 Jun 2026 |
| 12 May 2026 | 10-Q | 31 Mar 2026 |
| 12 May 2026 | 8-K | 12 May 2026 |
| 28 Apr 2026 | ARS | 31 Dec 2025 |
| 28 Apr 2026 | DEFA14A | – |
| 28 Apr 2026 | DEF 14A | 10 Jun 2026 |
| 9 Apr 2026 | 8-K | 8 Apr 2026 |
| 30 Mar 2026 | 10-K | 31 Dec 2025 |
| 26 Mar 2026 | 8-K | 26 Mar 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 19 May 2026 | Brodnax Brett, Director | Purchase | 35,000 | $7.25 | $253.8K | 62,027 | 21 May 2026 |
| 14 May 2026 | Cooper Henry Lee, Director | Purchase | 30,000 | $7.44 | $223.1K | 30,000 | 18 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | BROWN ADVISORY INC | 13G | 6.08% | 5.8M |
| 13 Feb 2026 | Welsh, Carson, Anderson & Stowe XII, L.P. | 13G | 74.3% | 70.2M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 1.9M | -5.17% | 5.63 |
| 30 Sep 2026 | 2.0M | -4.85% | 4.12 |
| 15 Sep 2026 | 2.1M | -18.45% | 7.33 |
| 31 Aug 2026 | 2.6M | +2.45% | 5.91 |
| 14 Aug 2026 | 2.5M | -7.84% | 4.5 |
| 31 Jul 2026 | 2.8M | +9.46% | 8.53 |
| 15 Jul 2026 | 2.5M | -10.69% | 4.49 |
| 30 Jun 2026 | 2.8M | -8.03% | 3.36 |
Funds that hold it
From each fund's latest Form 13F.
120 funds held it at 30 Jun 2026: 61 added and 29 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Brown Advisory Inc. | 5,777,574 | $65.2M | +4,072,497 |
| Massachusetts Financial Services Co. | 3,453,723 | $39.0M | +1,119,143 |
| Think Investments LP | 2,559,501 | $28.9M | +2,559,501 |
| Jupiter Topco LLC | 2,151,538 | $24.3M | – |
| BlackRock, Inc. | 1,398,112 | $15.8M | -127,571 |
| JPMorgan Chase & Co. | 1,154,463 | $13.3M | +49,956 |
| Vanguard Capital Management LLC | 1,070,325 | $12.1M | +11,839 |
| Goldman Sachs Group Inc. | 807,428 | $9.1M | +41,919 |
| Royce & Associates LP | 789,040 | $8.9M | +459,040 |
| Schonfeld Strategic Advisors LLC | 768,890 | $8.7M | +568,189 |
Peers
Companies in the same industry.
- Natera, Inc. (NTRA): revenue $2.7B, market value $59.5B
- Labcorp Holdings Inc. (LH): revenue $14.6B, market value $29.4B
- Quest Diagnostics Inc. (DGX): revenue $11.8B, market value $27.7B
- Guardant Health, Inc. (GH): revenue $1.2B, market value $23.9B
- Caris Life Sciences, Inc. (CAI): revenue $989.6M, market value $9.7B
- Grail, Inc. (GRAL): revenue $165.3M, market value $6.4B
- RadNet, Inc. (RDNT): revenue $2.3B, market value $5.8B
- BillionToOne, Inc. (BLLN): revenue $397.4M, market value $5.3B
- CareDx, Inc. (CDNA): revenue $497.4M, market value $4.6B
- Veracyte, Inc. (VCYT): revenue $561.9M, market value $4.0B